Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity ...
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025· Details of the Phase 3 ...
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the ...
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Host Tylah Tully looks at Alterity Therapeutics (ASX:ATH) and the highlighted multi billion dollar potential of its lead candidate for the rare neurodegenerative disease Multiple System Atrophy.
MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
The poster presentation can be found on Alterity’s website here.
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback